1,2-dichloroethane-acetone | 40449-35-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,2-dichloroethane-acetone
• 英文别名: 4,5-Dichlor-2-pentanon；4,5-Dichlor-pentanon-2；4,5-Dichloro-2-pentanone；4,5-dichloropentan-2-one
• CAS: 40449-35-2
• 化学式: C₅H₈Cl₂O
• mdl: MFCD19232209
• 分子量: 155.024
• InChiKey: KCCYRBFOCKEDLX-UHFFFAOYSA-N

物化性质

• 沸点：
  220.8±30.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2-dichloroethane-acetone 在 盐酸 、 三乙胺 作用下， 反应 26.0h， 生成 5-chloro-4-methoxy-2-pentanone
  参考文献：
  名称：

  A New and Convenient Method of Synthesis of γ-Ketoaldehydes

  摘要：

  描述了一种从酸氯化物和烯丙基氯出发的新合成方法，生成4-氧烷醛，该过程涉及烷基2,3-二氯丙酮、烷基3-氯丙烯酮、烷基3-氯-2-甲氧基丙酮以及1-烷酰基-2-甲氧基环丙烷的中间体。

  DOI：

  10.1055/s-1985-31427
• 作为产物：
  描述：

  乙酰氯 、 3-氯丙烯 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 生成 1,2-dichloroethane-acetone
  参考文献：
  名称：

  A New and Convenient Method of Synthesis of γ-Ketoaldehydes

  摘要：

  描述了一种从酸氯化物和烯丙基氯出发的新合成方法，生成4-氧烷醛，该过程涉及烷基2,3-二氯丙酮、烷基3-氯丙烯酮、烷基3-氯-2-甲氧基丙酮以及1-烷酰基-2-甲氧基环丙烷的中间体。

  DOI：

  10.1055/s-1985-31427

文献信息

• Analgesic and antipyretic pharmaceutical compositions containing a
  申请人：Dr. Karl Thomae Gesellschaft mit beschrankter Haftung

  公开号：US04353919A1

  公开（公告）日：1982-10-12

  Analgesic and antipyretic pharmaceutical dosage unit compositions containing as an active ingredient a compound of the formula ##STR1## wherein R.sub.5 is methyl or methoxy, and R.sub.4, R.sub.6 and R.sub.7 are hydrogen; or R.sub.6 is fluorine or chlorine, and R.sub.4, R.sub.5 and R.sub.7 are hydrogen; or R.sub.7 is chlorine, and R.sub.4, R.sub.5 and R.sub.6 are hydrogen; or R.sub.5 and R.sub.6 are methoxy, and R.sub.4 and R.sub.7 are hydrogen; or R.sub.4 is methyl or chlorine, and R.sub.5, R.sub.6 and R.sub.7 are hydrogen; and methods of using said compounds as analgesics and antipyretics.

  镇痛和退热药物剂量单位组合物，含有作为活性成分的化合物，其化学式为##STR1##其中R.sub.5为甲基或甲氧基，R.sub.4、R.sub.6和R.sub.7为氢；或R.sub.6为氟或氯，R.sub.4、R.sub.5和R.sub.7为氢；或R.sub.7为氯，R.sub.4、R.sub.5和R.sub.6为氢；或R.sub.5和R.sub.6为甲氧基，R.sub.4和R.sub.7为氢；或R.sub.4为甲基或氯，R.sub.5、R.sub.6和R.sub.7为氢；以及使用所述化合物作为镇痛和退热药物的方法。
• Compositions and methods for treatment of neoplastic disease
  申请人：——

  公开号：US20020177551A1

  公开（公告）日：2002-11-28

  The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

  本发明涉及一种用于治疗宿主体内肿瘤或肿瘤性疾病的组合物和方法。该方法采用包含超抗原多肽、具有其他结构的核酸和优先结合于肿瘤细胞并能够诱导细胞凋亡的结构的共轭物。还提供了超抗原-糖脂共轭物和负载于抗原呈递细胞上的囊泡，以激活T细胞和NKT细胞。基于细胞的疫苗包括肿瘤细胞，这些肿瘤细胞被改造以表达超抗原和糖脂产物，当这些细胞被引入哺乳动物体内时，这些细胞能够引起有效的抗肿瘤免疫反应。这些组合物包括肿瘤细胞、肿瘤细胞和辅助细胞的杂交细胞，优选为树突状细胞。还提供了无抑制性受体或抑制性信号基序的肿瘤细胞杀伤T细胞和NKT细胞，这些细胞对上述组合物和基于脂质的肿瘤相关抗原具有高度反应性，可用于癌症和传染病的免疫治疗。
• Procédé de synthèse organique d'oligosaccharides, correspondant à des fragments de muco-polysaccharides naturels, nouveaux oligosaccharides obtenus et leurs applications biologiques
  申请人：D.R.O.P.I.C. (Société Civile)

  公开号：EP0084999A1

  公开（公告）日：1983-08-03

  Procédé de synthèse organique d'oligosaccharides constituant ou correspondant à des fragments de muco-polysaccharides acides dans lequel on fait réagir deux composés constitués ou terminés respectivement par des motifs de structure sucre aminé et des motifs de structure acide uronique. Ces motifs étant substitués spécifiquement. Ce procédé conduit à des oligosaccharides utilisables notamment en thérapeutique.

  构成或对应于酸性粘多糖片段的低聚糖的有机合成工艺，其中两种分别由氨基糖结构单元和尿酸结构单元构成或终止的化合物发生反应。这些单元被特别取代。 这一过程产生的寡糖尤其可用于治疗。
• 5-flurorouracil derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0247381A2

  公开（公告）日：1987-12-02

  This invention relates to a 5-fluorouracil derivative represented by the formula wherein RY is a hydrogen atom or a specific acyl group, Z is a phenyl-lower alkoxy-lower alkyl group, thienyl-lower alkyl group optionally substituted with halogen atom on the thienyl ring, or a group wherein R1 and R2 are each a hydrogen atom, a specific acyl group, phenyl-lower alkyl group having a group RxOCO- on the phenyl ring, or a group -(A)nB, R" being a specific organic group, A being a lower alkylene group, n being 0 or 1, and B being a 5- or 6-membered unsaturated heterocyclic group having 1 to 4 hetero-atoms selected from nitrogen, oxygen and sulfur and optionally having a benzene ring, naphthalene ring or pyridine ring condensed therewith, with the proviso that when R is a hydrogen atom or acyl group, R2 is not a hydrogen atom or acyl group; to a process for preparing the same; to an anticancer composition comprising an effective amounts of the same; and to use of the same for preparation of an anticancer composition.

  本发明涉及一种 5-氟尿嘧啶衍生物，其式如下 其中 RY 是氢原子或特定酰基，Z 是苯基-低级烷氧基-低级烷基，噻吩基-低级烷基，可选择在噻吩基环上被卤素原子取代，或一个基团 其中 R1 和 R2 分别是氢原子、特定的酰基、苯基环上带有基团 RxOCO- 的苯基-低级烷基或基团-(A)nB，R "是特定的有机基团，A 是低级亚烷基，n 是 0 或 1、和 B 是 5 或 6 元不饱和杂环基团，具有 1 至 4 个选自氮、氧和硫的杂原子，并可选具有苯环、萘环或吡啶环，但当 R 是氢原子或酰基时，R2 不是氢原子或酰基；制备上述物质的工艺；包含有效量上述物质的抗癌组合物；以及使用上述物质制备抗癌组合物。
• Anti-fucosylceramide monoclonal antibody
  申请人：HOECHST JAPAN LIMITED

  公开号：EP0368222A1

  公开（公告）日：1990-05-16

  A monoclonal antibody PC47H specifically recognizing fucosylceramide derived from a ceramide-mono-glycoside fraction of neutral glycolipid extracted and purified from human cancer tissues and having properties such as belonging to IgM and showing reactivity to neither of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast nor cell lines derived from leukemia, hepatoma, breast cancer and neuroblastoma but to cell lines derived from lung cancer, stomach cancer, colon cancer and pancreas cancer; a hybridoma having an ability to produce the aforementioned monoclonal antibody; a method for manufacturing the aforementioned monoclonal antibody which comprises immunizing an animal with a neutral glycolipid fraction extracted from human pancreas cancer, fusing animal cells with myeloma cells to generate hybridomas, cloning the hybridomas, selecting clones which produce monoclonal antibodies which specifically recognize fucosylceramide and then using the clones to manufacture the monoclonal antibody; and a diagnostic of cancers such as lung cancer, stomach cancer, colon cancer and pancreas cancer containing the aforementioned monoclonal antibody as an active component.

  一种单克隆抗体 PC47H，特异性识别从人类癌症组织中提取和纯化的中性糖脂的神经酰胺-单糖苷部分衍生的岩藻糖基甘油酰胺，具有属于 IgM 的特性，对正常外周血淋巴细胞、正常红细胞、正常成纤维细胞或白血病、肝癌、乳腺癌和神经母细胞瘤细胞系均无反应性，但对肺癌、胃癌、结肠癌和胰腺癌细胞系有反应性；具有产生上述单克隆抗体能力的杂交瘤；一种制造上述单克隆抗体的方法，包括用从人胰腺癌中提取的中性糖脂部分对动物进行免疫，将动物细胞与骨髓瘤细胞融合产生杂交瘤，克隆杂交瘤，选择能产生特异性识别岩藻糖苷甘油酯的单克隆抗体的克隆，然后用克隆制造单克隆抗体；以及含有上述单克隆抗体作为活性成分的癌症诊断方法，如肺癌、胃癌、结肠癌和胰腺癌。